DALLAS, Dec. 7, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Generex Biotechnology Corp.(Nasdaq:GNBT). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
It is available at: http://www.beaconequity.com/i/GNBT
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Generex Biotechnology Corp. (GNBT) is engaged in the research, development and commercialization of drug delivery systems and technologies. The Company is in its development stage, and focuses on its technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. Its wholly owned subsidiaries include Generex Pharmaceuticals Inc., Antigen Express Inc., Generex (Bermuda) Inc., Generex Pharmaceuticals (USA) LLC and Generex Marketing & Distribution Inc.
In the report, the analyst notes:
"GNBT recently announced that the Company's proprietary Crave-NX(TM) 7-Day Diet Aid Spray will soon be available in Duane Reade's 256 drugstores throughout New York City. Crave-NX(TM) 7-Day Diet Aid Spray is a great tasting orange-flavored formulation, sprayed and administered into the mouth, scientifically formulated to quickly curb cravings throughout the day, saving valuable calories.
"The clinical trials of Generex Oral-lyn(TM) include patients with type 1 and type 2 diabetes. Incidence of type 1 diabetes is growing by 3% per year in children and adolescents, and at an alarming 5% per year among pre-school children. It is estimated that 70,000 children under the age of 15 develop type 1 diabetes each year -- a rate of almost 200 children each day. Currently, an estimated 440,000 children globally live with type 1 diabetes. Type 2 diabetes was once seen as a disease of adults, but is also growing at alarming rates in children and adolescents.
To read the entire report visit: http://www.beaconequity.com/i/GNBT
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.